ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by LSV Asset Management

LSV Asset Management trimmed its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 35.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 80,300 shares of the biotechnology company’s stock after selling 43,996 shares during the quarter. LSV Asset Management’s holdings in ADMA Biologics were worth $1,377,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ADMA. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in ADMA Biologics by 1.3% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company’s stock valued at $865,000 after acquiring an additional 645 shares during the last quarter. Oregon Public Employees Retirement Fund raised its position in ADMA Biologics by 1.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock valued at $954,000 after purchasing an additional 700 shares during the period. Mutual of America Capital Management LLC lifted its stake in shares of ADMA Biologics by 2.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock valued at $614,000 after purchasing an additional 751 shares during the last quarter. Maryland State Retirement & Pension System grew its holdings in shares of ADMA Biologics by 1.1% during the 4th quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company’s stock worth $1,365,000 after purchasing an additional 897 shares during the period. Finally, GAMMA Investing LLC increased its position in shares of ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 967 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Trading Up 7.8 %

Shares of NASDAQ ADMA opened at $20.91 on Tuesday. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $4.94 billion, a PE ratio of 74.68 and a beta of 0.53. ADMA Biologics, Inc. has a twelve month low of $5.91 and a twelve month high of $23.64. The stock has a fifty day simple moving average of $17.86 and a 200-day simple moving average of $18.16.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.